US Stock Market Move | Included in the Nasdaq 100 Index, Moderna (MRNA.US) rises 7%.

On Friday, Moderna (MRNA.US) rose as much as 10% intraday, hitting a new high since December 2022. As of press time, the gain had narrowed to 7%, at $210.95. On the news front, on October 9, Moderna was officially included in the Nasdaq 100 Index, replacing Warner Bros. Discovery. Following its inclusion, some broad-based institutions that previously did not allocate to biopharmaceuticals will hold the stock passively, while active institutions will also add the company to their watchlists, increasing attention on the stock. In addition, on October 7, the company expanded its multi-year collaboration with Merck & Co., Inc. and Tempus to provide tumor sample collection, sequencing, and therapy design and manufacturing support for the potential commercialization of the personalized neoantigen therapy intismeran autogene.